Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation

Autor: Mélissa Prat, Marie Salon, Thibault Allain, Olivier Dubreuil, Grégory Noël, Laurence Preisser, Bérangère Jean, Lydie Cassard, Fanny Lemée, Isabelle Tabah-Fish, Bernard Pipy, Pascale Jeannin, Jean-François Prost, Jean-Marc Barret, Agnès Coste

Publikováno v: Cancers
Cancers, 2021, 13 (8), pp.1845. ⟨10.3390/cancers13081845⟩
Volume 13
Issue 8
Cancers, MDPI, 2021, 13 (8), pp.1845. ⟨10.3390/cancers13081845⟩
Cancers, Vol 13, Iss 1845, p 1845 (2021)

Simple Summary AMHRII, the anti-Müllerian hormone receptor, is selectively expressed in normal sexual organs in healthy adults but is also re-expressed in ovarian, colorectal and lung cancers. In this context, we developed murlentamab, a humanized g

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::731de7b81f9fefcb383df07c1b5935e0
https://www.hal.inserm.fr/inserm-03215770